ABSTRACT
Introduction and Objective: Premature rupture of membranes [PROM] is one of the leading causes of preterm delivery and Potential adverse in prenatal. Given the importance of certain factors and lack of it's predisposing to this complication, this study aimed to investigate the relationship between PROM and the mother's blood lead level in first half of pregnancy.
Materials and Methods: This longitudinal study has done on 110 pregnant women at 14-20 weeks gestational age at clinics in teaching hospitals affiliated to Tehran University in the years 1389-1390.Obtainig blood samples to measure lead in enrollment and demographic and pregnancy questionnaire was completed. Data were analyzed by SPSS16 software and Corelation Spearman, UNICODE EXTENDED CHARACTER 2, Man-Whitney U, Linear regression tests and P<0.05 was taken as the significant level.
Results: The averagematernal age 26/7 +/- 4/3 years, the average maternal blood lead level of 4/7 +/- 4/9 MICRO SIGN g/dl and premature rupture of membranes 6/8% was reported. According to chi-square test results between blood lead and PROM, there was no significant relationship [P =0/8].
Conclusion: In this study, results showed there was no significant relationship between blood lead levels and premature rupture of membranes.
ABSTRACT
In recent years there has been considerable investigation about the potentials of soyfoods to reduce the risk of cancer, particularly breast cancer. Isoflavones are compounds with a chemical structure similar to estrogen and can bind to estrogen receptor. The relationship between soyfoods and breast cancer has become a controversial issue because of concerns-based mostly on some in vitro and rodent data-that isoflavones may stimulate the growth of existing estrogen-sensitive breast tumors. However; some have indicated that soy isoflavones have antitumor and antiproliferative effects. The epidemiologic data are generally consistent with the animal studies, showing no increased risk. In limited clinical studies there is no evidence that isoflavone intake increases tumor growth or proliferation of carcinoma cells. Also, epidemiological studies on breast cancer survival showed that soy isoflavones decrease recurrence and mortality of disease. Furthermore, it is demonstrated that in healthy women the pharmacologic dose of estrogen has very low if any risk for breast cancer. Because of the increasing popularity of soyfoods and the commercial availability of isoflavone supplements and existing concern regarding the estrogen-like effects of isoflavones in the breast, more clinical research seems to be necessary